Author: Selina McKee

AZ’ Farxiga shows CV benefit in diabetes patients

New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.

GW sells priority review voucher for $105m

GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.

Setback for Allergy’s birch pollen immunotherapy

Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.

EU regulators expand Praluent’s label

European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).

New lung cancer indication for Keytruda combo OK’d in EU

MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).